Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial
(2023)
Journal Article
Kelly, E., Greenland, M., de Whalley, P. C., Aley, P. K., Plested, E. L., Singh, N., …Com-COV3 Study Group, C. S. G. (2023). Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial. Journal of Infection, 87(3), 230-241. https://doi.org/10.1016/j.jinf.2023.06.007
Background: This was the first study to investigate the reactogenicity and immunogenicity of heterologous or fractional second dose COVID-19 vaccine regimens in adolescents. Methods: A phase II, single-blind, multi-centre, randomised-controlled trial... Read More about Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.